Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-09-11

FDA Approved: BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for the budesonide and formoterol fumarate dihydrate inhalation product from AstraZeneca (Symbicort).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Symbicort (budesonide/formoterol)

Snippet

SUPPL AP for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE)